Literature DB >> 30878562

Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design.

Marc O'Reilly1, Anne Cleasby1, Thomas G Davies1, Richard J Hall1, R Frederick Ludlow1, Christopher W Murray1, Dominic Tisi1, Harren Jhoti2.   

Abstract

We present a novel crystallographic screening methodology (MiniFrags) that employs high-concentration aqueous soaks with a chemically diverse and ultra-low-molecular-weight library (heavy atom count 5-7) to identify ligand-binding hot and warm spots on proteins. We propose that MiniFrag screening represents a highly effective method for guiding optimisation of fragment-derived lead compounds or chemical tools and that the high screening hit rates reflect enhanced sampling of chemical space.
Copyright © 2019 Astex Pharmaceuticals. Published by Elsevier Ltd.. All rights reserved.

Mesh:

Substances:

Year:  2019        PMID: 30878562     DOI: 10.1016/j.drudis.2019.03.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  19 in total

1.  Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation.

Authors:  Brian Fuglestad; Nicole E Kerstetter; Sabrina Bédard; A Joshua Wand
Journal:  ACS Chem Biol       Date:  2019-10-03       Impact factor: 5.100

2.  Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).

Authors:  Alexander D MacKerell; Sunhwan Jo; Sirish Kaushik Lakkaraju; Christoffer Lind; Wenbo Yu
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-01-03       Impact factor: 3.770

3.  Benchmark Sets for Binding Hot Spot Identification in Fragment-Based Ligand Discovery.

Authors:  Amanda E Wakefield; Christine Yueh; Dmitri Beglov; Marcelo S Castilho; Dima Kozakov; György M Keserű; Adrian Whitty; Sandor Vajda
Journal:  J Chem Inf Model       Date:  2020-12-08       Impact factor: 4.956

4.  Site-Resolved and Quantitative Characterization of Very Weak Protein-Ligand Interactions.

Authors:  Brian Fuglestad; Nicole E Kerstetter; A Joshua Wand
Journal:  ACS Chem Biol       Date:  2019-07-01       Impact factor: 5.100

5.  Comprehensive analysis of commercial fragment libraries.

Authors:  Julia Revillo Imbernon; Célien Jacquemard; Guillaume Bret; Gilles Marcou; Esther Kellenberger
Journal:  RSC Med Chem       Date:  2021-12-24

6.  Application of Site-Identification by Ligand Competitive Saturation in Computer-Aided Drug Design.

Authors:  Himanshu Goel; Anthony Hazel; Wenbo Yu; Sunhwan Jo; Alexander D MacKerell
Journal:  New J Chem       Date:  2021-11-29       Impact factor: 3.591

7.  SILCS-RNA: Toward a Structure-Based Drug Design Approach for Targeting RNAs with Small Molecules.

Authors:  Abhishek A Kognole; Anthony Hazel; Alexander D MacKerell
Journal:  J Chem Theory Comput       Date:  2022-08-01       Impact factor: 6.578

8.  Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.

Authors:  Paul Brear; Darby Ball; Katherine Stott; Sheena D'Arcy; Marko Hyvönen
Journal:  J Med Chem       Date:  2020-10-29       Impact factor: 7.446

9.  A Proof-of-Concept Fragment Screening of a Hit-Validated 96-Compounds Library against Human Carbonic Anhydrase II.

Authors:  Steffen Glöckner; Andreas Heine; Gerhard Klebe
Journal:  Biomolecules       Date:  2020-03-29

10.  Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.

Authors:  Alice Douangamath; Daren Fearon; Paul Gehrtz; Tobias Krojer; Petra Lukacik; C David Owen; Efrat Resnick; Claire Strain-Damerell; Anthony Aimon; Péter Ábrányi-Balogh; José Brandão-Neto; Anna Carbery; Gemma Davison; Alexandre Dias; Thomas D Downes; Louise Dunnett; Michael Fairhead; James D Firth; S Paul Jones; Aaron Keeley; György M Keserü; Hanna F Klein; Mathew P Martin; Martin E M Noble; Peter O'Brien; Ailsa Powell; Rambabu N Reddi; Rachael Skyner; Matthew Snee; Michael J Waring; Conor Wild; Nir London; Frank von Delft; Martin A Walsh
Journal:  Nat Commun       Date:  2020-10-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.